Development and characterization of cancer stem cell‐based tumoroids as an osteosarcoma model

Three‐dimensional (3D) cancer tumor models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems, and personalized medicine. Yet, it is becoming more evident that the tumor progression and metastasis is fueled by a subpopulation of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biotechnology and bioengineering 2020-08, Vol.117 (8), p.2527-2539
Hauptverfasser: Ozturk, Sukru, Gorgun, Cansu, Gokalp, Sevtap, Vatansever, Seda, Sendemir, Aylin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2539
container_issue 8
container_start_page 2527
container_title Biotechnology and bioengineering
container_volume 117
creator Ozturk, Sukru
Gorgun, Cansu
Gokalp, Sevtap
Vatansever, Seda
Sendemir, Aylin
description Three‐dimensional (3D) cancer tumor models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems, and personalized medicine. Yet, it is becoming more evident that the tumor progression and metastasis is fueled by a subpopulation of stem‐like cells within the tumor that are also called cancer stem cells (CSCs). This study aimed to develop a tumoroid model using CSCs. For this purpose CD133+ cells were isolated from SaOS‐2 osteosarcoma cell line with magnetic‐activated cell sorting. To evaluate tumoroid formation ability, the cells were incubated in different cell numbers in agar gels produced by 3D Petri Dish® method. Subsequently, CD133+ cells and CD133− cells were co‐cultured to investigate CD133+ cell localization in tumoroids. The characterization of tumoroids was performed using Live&Dead staining, immunohistochemistry, and quantitative polymerase chain reaction analysis. The results showed that, CD133+, CD133− and SaOS‐2 cells were all able to form 3D tumoroids regardless of the initial cell number, but, while 72 hr were needed for CD133+ cells to self‐assemble, 24 hr were enough for CD133− and SaOS‐2 cells. CD133+ cells were located within tumoroids randomly with high cell viability. Finally, when compared to two‐dimensional (2D) cultures, there were 5.88, 4.14, 6.95, and 1.68‐fold higher messenger RNA expressions for Sox2, OCT3/4, Nanog, and Nestin, respectively, in CD133+ cells that were cultured within 3D tumoroids, showing longer maintenance of stem cell phenotype in 3D, that can allow more relevant screening and targeting efficiency in pharmaceutical testing. It was concluded that CSC‐based tumoroids are propitious as 3D tumor models to fill the gap between conventional 2D in vitro culture and in vivo animal experiments for cancer research. Cancer stem cell (CSC)‐based 3D in vitro models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems and personalized medicine. Ozturk and coworkers developed and characterized a CSC‐based 3D tumoroid osteosarcoma model using a scaffold‐free 3D culture technique. The authors have shown that CSCs, unlike in 2D cultures, could maintain their stemness features with high cell viability in 3D tumoroids.
doi_str_mv 10.1002/bit.27381
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2401091656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2422435613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3901-c29405338e7e677926bdb705aa9ad88460c66e2b010052621395b37e4dbc01383</originalsourceid><addsrcrecordid>eNp10E1LwzAYB_AgipvTg19AAl700C0vbdocdb4NBC_zHNL0GXa0zUxaZZ78CH5GP4mZnR4EIRACv_x5nj9Cx5SMKSFskpftmKU8oztoSIlMI8Ik2UVDQoiIeCLZAB14vwzPNBNiHw0445JKFg-RuoIXqOyqhqbFuimwedJOmxZc-abb0jbYLrDRjQGHfQs1NlBVn-8fufZQ4LarrbNl4bEOJ9hArNfO2Frj2hZQHaK9ha48HG3vEXq8uZ5P76L7h9vZ9OI-MlwSGhkmY5JwnkEKIk0lE3mRpyTRWuoiy2JBjBDAchL2TZhglMsk5ynERW4I5RkfobM-d-Xscwe-VXXpN7PqBmznFYvDV0lFIgI9_UOXtnNNmC4oxmKeCMqDOu-VcdZ7Bwu1cmWt3VpRojatq9C6-m492JNtYpfXUPzKn5oDmPTgtaxg_X-SupzN-8gv2i-LXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2422435613</pqid></control><display><type>article</type><title>Development and characterization of cancer stem cell‐based tumoroids as an osteosarcoma model</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ozturk, Sukru ; Gorgun, Cansu ; Gokalp, Sevtap ; Vatansever, Seda ; Sendemir, Aylin</creator><creatorcontrib>Ozturk, Sukru ; Gorgun, Cansu ; Gokalp, Sevtap ; Vatansever, Seda ; Sendemir, Aylin</creatorcontrib><description>Three‐dimensional (3D) cancer tumor models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems, and personalized medicine. Yet, it is becoming more evident that the tumor progression and metastasis is fueled by a subpopulation of stem‐like cells within the tumor that are also called cancer stem cells (CSCs). This study aimed to develop a tumoroid model using CSCs. For this purpose CD133+ cells were isolated from SaOS‐2 osteosarcoma cell line with magnetic‐activated cell sorting. To evaluate tumoroid formation ability, the cells were incubated in different cell numbers in agar gels produced by 3D Petri Dish® method. Subsequently, CD133+ cells and CD133− cells were co‐cultured to investigate CD133+ cell localization in tumoroids. The characterization of tumoroids was performed using Live&amp;Dead staining, immunohistochemistry, and quantitative polymerase chain reaction analysis. The results showed that, CD133+, CD133− and SaOS‐2 cells were all able to form 3D tumoroids regardless of the initial cell number, but, while 72 hr were needed for CD133+ cells to self‐assemble, 24 hr were enough for CD133− and SaOS‐2 cells. CD133+ cells were located within tumoroids randomly with high cell viability. Finally, when compared to two‐dimensional (2D) cultures, there were 5.88, 4.14, 6.95, and 1.68‐fold higher messenger RNA expressions for Sox2, OCT3/4, Nanog, and Nestin, respectively, in CD133+ cells that were cultured within 3D tumoroids, showing longer maintenance of stem cell phenotype in 3D, that can allow more relevant screening and targeting efficiency in pharmaceutical testing. It was concluded that CSC‐based tumoroids are propitious as 3D tumor models to fill the gap between conventional 2D in vitro culture and in vivo animal experiments for cancer research. Cancer stem cell (CSC)‐based 3D in vitro models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems and personalized medicine. Ozturk and coworkers developed and characterized a CSC‐based 3D tumoroid osteosarcoma model using a scaffold‐free 3D culture technique. The authors have shown that CSCs, unlike in 2D cultures, could maintain their stemness features with high cell viability in 3D tumoroids.</description><identifier>ISSN: 0006-3592</identifier><identifier>EISSN: 1097-0290</identifier><identifier>DOI: 10.1002/bit.27381</identifier><identifier>PMID: 32391924</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Biomedical materials ; Bone cancer ; Cancer ; cancer stem cells ; CD133 ; Cell culture ; Cell number ; Cell viability ; Drug screening ; Gels ; Immunohistochemistry ; In vivo methods and tests ; Localization ; Metastases ; mRNA ; Nestin ; Oct-4 protein ; Osteosarcoma ; Phenotypes ; Polymerase chain reaction ; Precision medicine ; Screening ; Stem cell transplantation ; Stem cells ; Therapeutic targets ; Three dimensional models ; tumoroids ; Tumors ; Two dimensional models</subject><ispartof>Biotechnology and bioengineering, 2020-08, Vol.117 (8), p.2527-2539</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3901-c29405338e7e677926bdb705aa9ad88460c66e2b010052621395b37e4dbc01383</citedby><cites>FETCH-LOGICAL-c3901-c29405338e7e677926bdb705aa9ad88460c66e2b010052621395b37e4dbc01383</cites><orcidid>0000-0003-1818-6651 ; 0000-0002-0460-2952 ; 0000-0002-7415-9618 ; 0000-0001-9684-634X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbit.27381$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbit.27381$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32391924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ozturk, Sukru</creatorcontrib><creatorcontrib>Gorgun, Cansu</creatorcontrib><creatorcontrib>Gokalp, Sevtap</creatorcontrib><creatorcontrib>Vatansever, Seda</creatorcontrib><creatorcontrib>Sendemir, Aylin</creatorcontrib><title>Development and characterization of cancer stem cell‐based tumoroids as an osteosarcoma model</title><title>Biotechnology and bioengineering</title><addtitle>Biotechnol Bioeng</addtitle><description>Three‐dimensional (3D) cancer tumor models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems, and personalized medicine. Yet, it is becoming more evident that the tumor progression and metastasis is fueled by a subpopulation of stem‐like cells within the tumor that are also called cancer stem cells (CSCs). This study aimed to develop a tumoroid model using CSCs. For this purpose CD133+ cells were isolated from SaOS‐2 osteosarcoma cell line with magnetic‐activated cell sorting. To evaluate tumoroid formation ability, the cells were incubated in different cell numbers in agar gels produced by 3D Petri Dish® method. Subsequently, CD133+ cells and CD133− cells were co‐cultured to investigate CD133+ cell localization in tumoroids. The characterization of tumoroids was performed using Live&amp;Dead staining, immunohistochemistry, and quantitative polymerase chain reaction analysis. The results showed that, CD133+, CD133− and SaOS‐2 cells were all able to form 3D tumoroids regardless of the initial cell number, but, while 72 hr were needed for CD133+ cells to self‐assemble, 24 hr were enough for CD133− and SaOS‐2 cells. CD133+ cells were located within tumoroids randomly with high cell viability. Finally, when compared to two‐dimensional (2D) cultures, there were 5.88, 4.14, 6.95, and 1.68‐fold higher messenger RNA expressions for Sox2, OCT3/4, Nanog, and Nestin, respectively, in CD133+ cells that were cultured within 3D tumoroids, showing longer maintenance of stem cell phenotype in 3D, that can allow more relevant screening and targeting efficiency in pharmaceutical testing. It was concluded that CSC‐based tumoroids are propitious as 3D tumor models to fill the gap between conventional 2D in vitro culture and in vivo animal experiments for cancer research. Cancer stem cell (CSC)‐based 3D in vitro models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems and personalized medicine. Ozturk and coworkers developed and characterized a CSC‐based 3D tumoroid osteosarcoma model using a scaffold‐free 3D culture technique. The authors have shown that CSCs, unlike in 2D cultures, could maintain their stemness features with high cell viability in 3D tumoroids.</description><subject>Biomedical materials</subject><subject>Bone cancer</subject><subject>Cancer</subject><subject>cancer stem cells</subject><subject>CD133</subject><subject>Cell culture</subject><subject>Cell number</subject><subject>Cell viability</subject><subject>Drug screening</subject><subject>Gels</subject><subject>Immunohistochemistry</subject><subject>In vivo methods and tests</subject><subject>Localization</subject><subject>Metastases</subject><subject>mRNA</subject><subject>Nestin</subject><subject>Oct-4 protein</subject><subject>Osteosarcoma</subject><subject>Phenotypes</subject><subject>Polymerase chain reaction</subject><subject>Precision medicine</subject><subject>Screening</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Therapeutic targets</subject><subject>Three dimensional models</subject><subject>tumoroids</subject><subject>Tumors</subject><subject>Two dimensional models</subject><issn>0006-3592</issn><issn>1097-0290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp10E1LwzAYB_AgipvTg19AAl700C0vbdocdb4NBC_zHNL0GXa0zUxaZZ78CH5GP4mZnR4EIRACv_x5nj9Cx5SMKSFskpftmKU8oztoSIlMI8Ik2UVDQoiIeCLZAB14vwzPNBNiHw0445JKFg-RuoIXqOyqhqbFuimwedJOmxZc-abb0jbYLrDRjQGHfQs1NlBVn-8fufZQ4LarrbNl4bEOJ9hArNfO2Frj2hZQHaK9ha48HG3vEXq8uZ5P76L7h9vZ9OI-MlwSGhkmY5JwnkEKIk0lE3mRpyTRWuoiy2JBjBDAchL2TZhglMsk5ynERW4I5RkfobM-d-Xscwe-VXXpN7PqBmznFYvDV0lFIgI9_UOXtnNNmC4oxmKeCMqDOu-VcdZ7Bwu1cmWt3VpRojatq9C6-m492JNtYpfXUPzKn5oDmPTgtaxg_X-SupzN-8gv2i-LXg</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Ozturk, Sukru</creator><creator>Gorgun, Cansu</creator><creator>Gokalp, Sevtap</creator><creator>Vatansever, Seda</creator><creator>Sendemir, Aylin</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QO</scope><scope>7QQ</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7T7</scope><scope>7TA</scope><scope>7TB</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>C1K</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>JG9</scope><scope>JQ2</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1818-6651</orcidid><orcidid>https://orcid.org/0000-0002-0460-2952</orcidid><orcidid>https://orcid.org/0000-0002-7415-9618</orcidid><orcidid>https://orcid.org/0000-0001-9684-634X</orcidid></search><sort><creationdate>202008</creationdate><title>Development and characterization of cancer stem cell‐based tumoroids as an osteosarcoma model</title><author>Ozturk, Sukru ; Gorgun, Cansu ; Gokalp, Sevtap ; Vatansever, Seda ; Sendemir, Aylin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3901-c29405338e7e677926bdb705aa9ad88460c66e2b010052621395b37e4dbc01383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomedical materials</topic><topic>Bone cancer</topic><topic>Cancer</topic><topic>cancer stem cells</topic><topic>CD133</topic><topic>Cell culture</topic><topic>Cell number</topic><topic>Cell viability</topic><topic>Drug screening</topic><topic>Gels</topic><topic>Immunohistochemistry</topic><topic>In vivo methods and tests</topic><topic>Localization</topic><topic>Metastases</topic><topic>mRNA</topic><topic>Nestin</topic><topic>Oct-4 protein</topic><topic>Osteosarcoma</topic><topic>Phenotypes</topic><topic>Polymerase chain reaction</topic><topic>Precision medicine</topic><topic>Screening</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Therapeutic targets</topic><topic>Three dimensional models</topic><topic>tumoroids</topic><topic>Tumors</topic><topic>Two dimensional models</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ozturk, Sukru</creatorcontrib><creatorcontrib>Gorgun, Cansu</creatorcontrib><creatorcontrib>Gokalp, Sevtap</creatorcontrib><creatorcontrib>Vatansever, Seda</creatorcontrib><creatorcontrib>Sendemir, Aylin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics &amp; Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Materials Business File</collection><collection>Mechanical &amp; Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ANTE: Abstracts in New Technology &amp; Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts – Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biotechnology and bioengineering</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ozturk, Sukru</au><au>Gorgun, Cansu</au><au>Gokalp, Sevtap</au><au>Vatansever, Seda</au><au>Sendemir, Aylin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and characterization of cancer stem cell‐based tumoroids as an osteosarcoma model</atitle><jtitle>Biotechnology and bioengineering</jtitle><addtitle>Biotechnol Bioeng</addtitle><date>2020-08</date><risdate>2020</risdate><volume>117</volume><issue>8</issue><spage>2527</spage><epage>2539</epage><pages>2527-2539</pages><issn>0006-3592</issn><eissn>1097-0290</eissn><abstract>Three‐dimensional (3D) cancer tumor models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems, and personalized medicine. Yet, it is becoming more evident that the tumor progression and metastasis is fueled by a subpopulation of stem‐like cells within the tumor that are also called cancer stem cells (CSCs). This study aimed to develop a tumoroid model using CSCs. For this purpose CD133+ cells were isolated from SaOS‐2 osteosarcoma cell line with magnetic‐activated cell sorting. To evaluate tumoroid formation ability, the cells were incubated in different cell numbers in agar gels produced by 3D Petri Dish® method. Subsequently, CD133+ cells and CD133− cells were co‐cultured to investigate CD133+ cell localization in tumoroids. The characterization of tumoroids was performed using Live&amp;Dead staining, immunohistochemistry, and quantitative polymerase chain reaction analysis. The results showed that, CD133+, CD133− and SaOS‐2 cells were all able to form 3D tumoroids regardless of the initial cell number, but, while 72 hr were needed for CD133+ cells to self‐assemble, 24 hr were enough for CD133− and SaOS‐2 cells. CD133+ cells were located within tumoroids randomly with high cell viability. Finally, when compared to two‐dimensional (2D) cultures, there were 5.88, 4.14, 6.95, and 1.68‐fold higher messenger RNA expressions for Sox2, OCT3/4, Nanog, and Nestin, respectively, in CD133+ cells that were cultured within 3D tumoroids, showing longer maintenance of stem cell phenotype in 3D, that can allow more relevant screening and targeting efficiency in pharmaceutical testing. It was concluded that CSC‐based tumoroids are propitious as 3D tumor models to fill the gap between conventional 2D in vitro culture and in vivo animal experiments for cancer research. Cancer stem cell (CSC)‐based 3D in vitro models are becoming vital approaches for high‐throughput drug screening, drug targeting, development of novel theranostic systems and personalized medicine. Ozturk and coworkers developed and characterized a CSC‐based 3D tumoroid osteosarcoma model using a scaffold‐free 3D culture technique. The authors have shown that CSCs, unlike in 2D cultures, could maintain their stemness features with high cell viability in 3D tumoroids.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32391924</pmid><doi>10.1002/bit.27381</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-1818-6651</orcidid><orcidid>https://orcid.org/0000-0002-0460-2952</orcidid><orcidid>https://orcid.org/0000-0002-7415-9618</orcidid><orcidid>https://orcid.org/0000-0001-9684-634X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0006-3592
ispartof Biotechnology and bioengineering, 2020-08, Vol.117 (8), p.2527-2539
issn 0006-3592
1097-0290
language eng
recordid cdi_proquest_miscellaneous_2401091656
source Wiley Online Library Journals Frontfile Complete
subjects Biomedical materials
Bone cancer
Cancer
cancer stem cells
CD133
Cell culture
Cell number
Cell viability
Drug screening
Gels
Immunohistochemistry
In vivo methods and tests
Localization
Metastases
mRNA
Nestin
Oct-4 protein
Osteosarcoma
Phenotypes
Polymerase chain reaction
Precision medicine
Screening
Stem cell transplantation
Stem cells
Therapeutic targets
Three dimensional models
tumoroids
Tumors
Two dimensional models
title Development and characterization of cancer stem cell‐based tumoroids as an osteosarcoma model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T09%3A57%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20characterization%20of%20cancer%20stem%20cell%E2%80%90based%20tumoroids%20as%20an%20osteosarcoma%20model&rft.jtitle=Biotechnology%20and%20bioengineering&rft.au=Ozturk,%20Sukru&rft.date=2020-08&rft.volume=117&rft.issue=8&rft.spage=2527&rft.epage=2539&rft.pages=2527-2539&rft.issn=0006-3592&rft.eissn=1097-0290&rft_id=info:doi/10.1002/bit.27381&rft_dat=%3Cproquest_cross%3E2422435613%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2422435613&rft_id=info:pmid/32391924&rfr_iscdi=true